
Medtronic plc (NYSE:MDT) Wednesday announced the commencement of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to assess the safety and effectiveness of its Hugo robotic-assisted surgery (RAS) system in gynecological procedures.
This marks a significant step in the company’s strategy to expand its minimally invasive treatment options for patients in the U.S. market.